RKRadomir Kratchmarov

Radomir Kratchmarov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Radomir Kratchmarov has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progenitor T cells drive chronic pulmonary type 2 inflammation

    by Radomir Kratchmarov, Xiaojiong Jia, Jun Nagai, Gaspar A. Pacheco, Alexander Perniss, Madeleine R. Bell, Ersin Gül, Thornton W. Thompson, Hiroaki Hayashi, Shahab Saghaei, et al.

    Type 2 inflammation is coordinated by remarkably durable CD4+ T helper 2 (TH2) cell responses, yet the cellular architecture that drives this chronic inflammation and prevents exhaustion remains poorly understood. To define the TH2 landscape in chronic type 2 inflammation, we established a mouse model of long-term pulmonary allergen exposure, finding that type 2 inflammation was broadly sustained over time and included an expanded T cell factor 1-expressing progenitor-like population. In vivo, lung TH2 progenitors were sufficient to both initiate and sustain type 2 inflammation, coupling self-renewal with effector cell differentiation. Transcriptomic and spatial deconstruction of chronic pulmonary TH2 responses identified interleukin-7 receptor signaling and lung tissue B cell infiltration in the context of tertiary lymphoid structure formation as key factors contributing to the maintenance of TH2 progenitors. Our data define the TH2 progenitor as a distinct cellular state arising during pathogenic chronic type 2 inflammation with a central role in sustaining TH2 responses over time.

  • Open Access

    Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

  • Open Access

    Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

    Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.

  • Open Access

    Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

  • Open Access

    Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

  • Open Access

    Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

    Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.

  • Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

    Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.


  • Open Access

    CD4+ T cell effector commitment coupled to self-renewal by asymmetric cell divisions

    by Simone A. Nish, Kyra D. Zens, Radomir Kratchmarov, Wen-Hsuan W. Lin, William C. Adams, Yen-Hua Chen, Bonnie Yen, Nyanza J. Rothman, Avinash Bhandoola, Hai-Hui Xue, et al.

    Upon infection, an activated CD4+ T cell produces terminally differentiated effector cells and renews itself for continued defense. In this study, we show that differentiation and self-renewal arise as opposing outcomes of sibling CD4+ T cells. After influenza challenge, antigen-specific cells underwent several divisions in draining lymph nodes (LN; DLNs) while maintaining expression of TCF1. After four or five divisions, some cells silenced, whereas some cells maintained TCF1 expression. TCF1-silenced cells were T helper 1–like effectors and concentrated in the lungs. Cells from earliest divisions were memory-like and concentrated in nondraining LN. TCF1-expressing cells from later divisions in the DLN could self-renew, clonally yielding a TCF1-silenced daughter cell as well as a sibling cell maintaining TCF1 expression. Some TCF1-expressing cells in DLNs acquired an alternative, follicular helper-like fate. Modeled differentiation experiments in vitro suggested that unequal PI3K/mechanistic target of rapamycin signaling drives intraclonal cell fate heterogeneity. Asymmetric division enables self-renewal to be coupled to production of differentiated CD4+ effector T cells during clonal selection.


  • Open Access

    Anabolism-Associated Mitochondrial Stasis Driving Lymphocyte Differentiation over Self-Renewal

    by William C. Adams, Yen-Hua Chen, Radomir Kratchmarov, Bonnie Yen, Simone A. Nish, Wen-Hsuan W. Lin, Nyanza J. Rothman, Larry L. Luchsinger, Ulf Klein, Meinrad Busslinger, et al.


  • Open Access

    CD8+ T Lymphocyte Self-Renewal during Effector Cell Determination

    by Wen-Hsuan W. Lin, Simone A. Nish, Bonnie Yen, Yen-Hua Chen, William C. Adams, Radomir Kratchmarov, Nyanza J. Rothman, Avinash Bhandoola, Hai-Hui Xue, Steven L. Reiner